Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.53 |
| ▸ | MC4R | P32245 | 2/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 8/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30264726 | 1.00 | GHSR (0.53) | GHSRMC4RKISS1RC5AR1 | |
| SCHEMBL31555126 | 0.94 | MC4R (0.49) | GHSRMC4RKISS1RC5AR1 | |
| SCHEMBL29476499 | 0.93 | MC4R (0.50) | GHSRMC4RKISS1RC5AR1 | |
| SCHEMBL29476495 | 0.93 | TUBB4A (0.51) | GHSRMC4RKISS1RC5AR1 | |
| SCHEMBL29531021 | 0.93 | TUBB4A (0.51) | GHSRMC4RKISS1RC5AR1 | |
| SCHEMBL31620051 | 0.93 | TUBB4A (0.51) | GHSRMC4RKISS1RC5AR1 | |
| SCHEMBL28675578 | 0.93 | MC4R (0.53) | GHSRMC4RKISS1R | |
| SCHEMBL30264755 | 0.93 | GHSR (0.61) | GHSRMC4RKISS1R | |
| SCHEMBL30264983 | 0.93 | C5AR1 (0.51) | GHSRMC4RKISS1RC5AR1 | |
| SCHEMBL30264997 | 0.93 | C5AR1 (0.51) | GHSRMC4RKISS1RC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240391954-A1 | MC4R AGONIST PEPTIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-11-28 | — | — | US | disclosed |
| US-20240182519-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA S.A.S. (FR) | 2024-06-06 | — | — | US | disclosed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4216979-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
| WO-2022067086-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391954-A1 | MC4R AGONIST PEPTIDES | MC4R, MC3R, MC5R | GHSR 24/4885MC4R 1/4885KISS1R 72/4885 |
| US-20240182519-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | MC4R, MC3R, MC1R | GHSR 102/4885MC4R 1/4885KISS1R 81/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | GHSR 33/4885MC4R 1/4885KISS1R 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.